Azad Engineering Board Announces Re-appointment of Key Leadership Team

Azad Engineering has officially announced the re-appointment of its core leadership team, including Mr. Rakesh Chopdar as Whole-Time Director, Executive Chairman, and CEO. Additionally, Mrs. Jyoti Chopdar and Mr. Vishnu Malpani have been re-appointed as Whole-Time Directors. These terms are set for a duration of five years, effective from September 13, 2026, subject to the formal approval of the company’s shareholders at the upcoming Annual General Meeting.

Strategic Leadership Continuity

Azad Engineering has confirmed the decision to extend the tenures of its top leadership team to ensure sustained growth and strategic continuity. Following a Board meeting held on May 12, 2026, the company announced that Mr. Rakesh Chopdar will continue to lead the organization as the Whole-Time Director, Executive Chairman, and Chief Executive Officer for another five-year term starting September 13, 2026.

Strengthening the Executive Board

Alongside the leadership renewal of its founder, the Board has also approved the re-appointment of two other integral directors. Mrs. Jyoti Chopdar, who has been instrumental in streamlining administrative functions and processes over the past eight years, will continue her role as Whole-Time Director. Similarly, Mr. Vishnu Malpani will maintain his position as Executive Director. Mr. Malpani is tasked with driving the company’s enterprise strategy, capital formation, and organizational scale-up, with a clear focus on achieving 10x growth in the coming years.

Looking Ahead

The company continues to serve a global client base, including major OEMs such as GE Vernova, Mitsubishi, Siemens, and Boeing. This leadership renewal is designed to maintain the company’s focus on long-term value creation, corporate governance, and its commitment to the aerospace, defense, and energy sectors. The formal ratification for these appointments will be sought from shareholders at the Annual General Meeting.

Source: BSE

Previous Article

Eris Lifesciences India Ratings Affirms Credit Rating for Subsidiary Eris Therapeutics

Next Article

Sagility Limited Strong Financial Growth Reported for FY26